secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001104659-25-055181
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics Phase 1 data: VCN-01 well-tolerated in retinoblastoma; eye preserved in 3 of 9 patients
--------------------------------------------------------------------------------

- VCN-01 intravitreal injection at 2E+10 vp/eye was well-tolerated; no retinal toxicity or DLTs; main AE Grade 1-2 uveitis.
- Four of nine patients had improvement in vitreous seed density; 3 avoided enucleation with follow-up up to 49 months.
- No Grade >=3 ocular or systemic toxicities; selective replication in tumor cells confirmed by immunohistochemistry.
- RP2D defined as 2 doses of 2E+10 vp/eye; VCN-01 genomes in aqueous humor correlated with vitreous seed persistence.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465925055181/0001104659-25-055181-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465925055181/tm2516499d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-055181

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer